Diabetes & CVD: Time for a multifactorial approach
Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.
Video navigation menu
- Diabetes patients have a high CV risk 00:30
- New treatment goals in diabetes to reduce CV complications 02:36
- Major CV benefits with 2 new classes of drugs 05:00
- New drugs:: trial data and unanswered questions 08:43
- How can diabetes with associated CVD be prevented? 10:56
- Conclusion: new era for treatment of diabetes & CVD 16:42
This lecture by prof. John E Deanfield was part of a CME-accredited symposium "Diabetes, Cardiology & Novel Therapeutic Approaches" held during WCC 2018 in Dubai.
Prof. John E. Deanfield, MD - Professor of Cardiology - Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.